Amylyx Pharmaceuticals, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Amylyx Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $190.74M.
- Amylyx Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $65.58M.
- Amylyx Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2023-03-31 was $2.78M, a 98.59% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2022-03-31 was $196.38M.
- Amylyx Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2025 was $256.31M.
- Amylyx Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2022 was $196.38M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $256.31M 10-K · filed 2026-03-03 | |
| 2025-09-30 | $190.74M 10-Q · filed 2025-11-06 | |
| 2025-03-31 | $65.58M 10-Q · filed 2026-08-06 | |
| 2023-03-31 | $2.78M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $196.38M 10-K · filed 2024-02-22 | |
| 2022-03-31 | $196.38M 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |